SCHEMBL6249376

SCHEMBL6249376

O=C1C=CCc2c1ccc1ccccc21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.49
HPGD P15428 3/20 0.49
CYP2C19 P33261 3/20 0.49
ALDH1A1 P00352 3/20 0.49
CYP2C9 P11712 2/20 0.49
MEN1 O00255 1/20 0.49
USP2 O75604 1/20 0.49
LMNA P02545 1/20 0.49
TP53 P04637 1/20 0.49
CYP2D6 P10635 1/20 0.49
ALOX12 P18054 1/20 0.49
MAPK1 P28482 1/20 0.49
KMT2A Q03164 1/20 0.49
HIF1A Q16665 1/20 0.49
KDM4E B2RXH2 2/20 0.43
HTT P42858 1/20 0.43
CDK5 Q00535 1/20 0.43
CDK5R1 Q15078 1/20 0.43
NCOA1 Q15788 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2990894 0.79 HSD17B10 (0.40) CYP1A2HPGDCYP2C19ALDH1A1CYP2C9
SCHEMBL1395078 0.79 ALDH1A1 (0.38) CYP1A2HPGDCYP2C19ALDH1A1CYP2C9
SCHEMBL8368595 0.75 PAX8 (0.47) CYP1A2HPGDCYP2C19ALDH1A1CYP2C9
SCHEMBL10446466 0.75 TDP1 (0.35) CYP1A2HPGDCYP2C19ALDH1A1CYP2C9
SCHEMBL2290546 0.73 HSD17B10 (0.44) CYP1A2HPGDCYP2C19ALDH1A1CYP2C9
SCHEMBL29399101 0.73 HSD17B10 (0.44) CYP1A2HPGDCYP2C19ALDH1A1CYP2C9
SCHEMBL31450268 0.72 HSD17B10 (0.42) CYP1A2HPGDCYP2C19ALDH1A1CYP2C9
Benzene SCHEMBL1724439 0.72 HSD17B10 (0.42) CYP1A2HPGDCYP2C19ALDH1A1CYP2C9
SCHEMBL13346263 0.71 CES1 (0.46) CYP1A2HPGDCYP2C19ALDH1A1CYP2C9
SCHEMBL29563614 0.71 ALDH1A1 (0.41) CYP1A2HPGDCYP2C19ALDH1A1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130597-A1 DNA-PKCS MODULATES ENERGY REGULATION AND BRAIN FUNCTION THE UNITED STATE OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPT OF HEALTH AND HUMAN SERVICE (US) 2010-05-27 US disclosed
EP-1399406-B1 NOVEL ESTROGEN RECEPTOR LIGANDS AND METHODS I KAROBIO AB (SE) 2005-08-10 EP disclosed
EP-0872903-B1 Method for making hydrogen storage alloy powder and electrode comprising the alloy powder SHINETSU CHEMICAL CO (JP) 2001-10-04 EP disclosed
US-6277519-B1 QUENCHING AN ALLOY MELT; COMMINUTION SHIN-ETSU CHEMICAL CO., LTD. (JP) 2001-08-21 US disclosed
EP-0872903-A1 Method for making hydrogen storage alloy powder and electrode comprising the alloy powder Shin-Etsu Chemical Co., Ltd. (JP) 1998-10-21 EP disclosed
EP-0172427-B1 PROCESS FOR PRODUCTION OF VINYL CHLORIDE POLYMER Shin-Etsu Chemical Co., Ltd. (JP) 1989-07-05 EP disclosed
US-4758639-A Process for production of vinyl polymer SHIN-ETSU CHEMICAL CO., LTD. (JP) 1988-07-19 US disclosed
US-4757124-A Suspension or emulsion polymerizing vinyl chloride monomer or mixture of vinyl chloride with vinyl monomer copolymerizable therewith in reactor with walls coated with antiscaling compound containing dye or pigments SHIN-ETSU CHEMICAL CO., LTD. (JP) 1988-07-12 US disclosed
EP-0172427-A2 Process for production of vinyl chloride polymer Shin-Etsu Chemical Co., Ltd. (JP) 1986-02-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130597-A1 DNA-PKCS MODULATES ENERGY REGULATION AND BRAIN FUNCTION PRKAB1, PRKAG1, PRKAB2 CYP1A2 4710/4885HPGD 2290/4885CYP2C19 4668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.